Ad
related to: who should not take zantac
Search results
Results from the WOW.Com Content Network
Ranitidine. Ranitidine, previously sold under the brand name Zantac[a] among others, is a medication used to decrease stomach acid production. [12] It was commonly used in treatment of peptic ulcer disease, gastroesophageal reflux disease, and Zollinger–Ellison syndrome. [12]
A Delaware judge rebuffed a request by GSK and other drugmakers to appeal a ruling allowing more than 70,000 lawsuits claiming that the heartburn drug Zantac caused cancer to go forward. The ...
Some tests showed that Zantac's active ingredient, ranitidine, could degrade into NDMA over time or when exposed to heat. The U.S. Food and Drug Administration asked manufacturers to pull the drug ...
Shortly afterwards, lawsuits began piling up from people who said they developed cancer after taking Zantac. Plaintiffs said the companies knew, or should have known, that ranitidine posed a ...
Zantac was first marketed in 1981, [7] and it was described in 1989 as "one of the most expensive drugs on the market", [8] and "the world's biggest-selling prescription drug". [9] Addiction to taking it ("a habit") was how some of its users described Zantac. [10] The focus of Glaxo, its manufacturer, was to gain market share "from Zantac ...
The jury found that Valadez proved that she had taken Zantac, but not that it was a cause of her cancer. First approved in 1983, Zantac became the world's best selling medicine in 1988 and one of ...
Zantac can refer to either of two different H 2 antagonists used to reduce gastric acid secretion: Ranitidine, prior to its 2020 withdrawal from the market. Famotidine, following the withdrawal of ranitidine. Categories: Disambiguation pages. Drugs developed by GSK plc.
Brendan Pierson. June 1, 2024 at 9:17 PM. By Brendan Pierson. (Reuters) -A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that ...
Ad
related to: who should not take zantac